MedPath

Mitoxantrone

MitoXANTRONE Injection, USP (concentrate)

Approved
Approval ID

accf9569-4b57-4e83-a7db-4e890a75d1ba

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 15, 2022

Manufacturers
FDA

Hospira, Inc.

DUNS: 141588017

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Mitoxantrone

PRODUCT DETAILS

NDC Product Code61703-343
Application NumberANDA076871
Marketing CategoryC73584
Route of AdministrationINTRAVENOUS
Effective DateApril 15, 2022
Generic NameMitoxantrone

INGREDIENTS (6)

MITOXANTRONE HYDROCHLORIDEActive
Quantity: 2 mg in 1 mL
Code: U6USW86RD0
Classification: ACTIM
SODIUM ACETATEInactive
Code: 4550K0SC9B
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
ACETIC ACIDInactive
Code: Q40Q9N063P
Classification: IACT
SODIUM METABISULFITEInactive
Code: 4VON5FNS3C
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Mitoxantrone - FDA Drug Approval Details